{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:25:24Z","timestamp":1793395524584,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.amjms.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T12:08:08Z","timestamp":1678709288000},"page":"3-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pulmonary hypertension inhaled therapies: An updated review"],"prefix":"10.1016","volume":"366","author":[{"given":"Karim","family":"El-Kersh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilal A.","family":"Jalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.amjms.2023.03.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.024969","article-title":"Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry","volume":"11","author":"Chang","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.amjms.2023.03.002_bib0002","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","author":"Humbert","year":"2022","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.amjms.2023.03.002_bib0003","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1183\/09031936.00097107","article-title":"Prostacyclin therapies for the treatment of pulmonary arterial hypertension","volume":"31","author":"Gomberg-Maitland","year":"2008","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.amjms.2023.03.002_bib0004","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1378\/chest.124.4.1294","article-title":"Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension","volume":"124","author":"Olschewski","year":"2003","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.amjms.2023.03.002_bib0005","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa020204","article-title":"Inhaled iloprost for severe pulmonary hypertension","volume":"347","author":"Olschewski","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.amjms.2023.03.002_bib0006","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.06.00057906","article-title":"Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension","volume":"28","author":"Hoeper","year":"2006","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.amjms.2023.03.002_bib0007","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1164\/rccm.200603-358OC","article-title":"Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension","volume":"174","author":"McLaughlin","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.amjms.2023.03.002_bib0008","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.rmed.2010.01.008","article-title":"Long-term therapy with inhaled iloprost in patients with pulmonary hypertension","volume":"104","author":"Olschewski","year":"2010","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.amjms.2023.03.002_bib0009","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1253\/circj.CJ-16-0097","article-title":"Efficacy and safety of inhaled iloprost in japanese patients with pulmonary arterial hypertension - insights from the IBUKI and AIR studies","volume":"80","author":"Saji","year":"2016","journal-title":"Circ J"},{"issue":"2","key":"10.1016\/j.amjms.2023.03.002_bib0010","doi-asserted-by":"crossref","first-page":"e12074","DOI":"10.1002\/pul2.12074","article-title":"Inhaled iloprost induces long-term beneficial hemodynamic changes in patients with pulmonary arterial hypertension receiving combination therapy","volume":"12","author":"Yasuda","year":"2022","journal-title":"Pulm Circ"},{"issue":"1","key":"10.1016\/j.amjms.2023.03.002_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1164\/rccm.202201-0095LE","article-title":"Inhaled Iloprost improves right ventricular load-independent contractility in pulmonary hypertension","volume":"206","author":"Tello","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.amjms.2023.03.002_bib0012","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/DDDT.S19281","article-title":"Inhaled treprostinil: a therapeutic review","volume":"6","author":"Channick","year":"2012","journal-title":"Drug Des Devel Ther"},{"issue":"6","key":"10.1016\/j.amjms.2023.03.002_bib0013","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1152\/japplphysiol.00083.2005","article-title":"Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation","volume":"99","author":"Sandifer","year":"1985","journal-title":"J Appl Physiol"},{"issue":"18","key":"10.1016\/j.amjms.2023.03.002_bib0014","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.amjms.2023.03.002_bib0015","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","article-title":"Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the treprostinil sodium inhalation used in the management of pulmonary arterial hypertension (TRIUMPH) study open-label extension","volume":"30","author":"Benza","year":"2011","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.amjms.2023.03.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1177\/2045894020977025","article-title":"Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies","volume":"10","author":"Tonelli","year":"2020","journal-title":"Pulm Circ"},{"issue":"4","key":"10.1016\/j.amjms.2023.03.002_bib0017","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211052228","article-title":"Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54\u2009\u00b5g (nine breaths) four times daily","volume":"11","author":"Shapiro","year":"2021","journal-title":"Pulm Circ"},{"issue":"4","key":"10.1016\/j.amjms.2023.03.002_bib0018","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjms.2023.03.002_bib0019","series-title":"Proceedings of the annual world congress of the pulmonary vascular research institute","first-page":"A021","article-title":"The importance of early treatment with inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease: a post-hoc analysis of the INCREASE open-label extension","author":"Nathan VFT","year":"2022"},{"key":"10.1016\/j.amjms.2023.03.002_bib0020","article-title":"Inhaled treprostinil dosage in pulmonary hypertension associated with interstitial lung disease and its effects on clinical outcomes","author":"Nathan","year":"2022","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.amjms.2023.03.002_bib0021","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(20)30532-4","article-title":"Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial","volume":"9","author":"Hoeper","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.amjms.2023.03.002_bib0022","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1164\/rccm.202107-1766OC","article-title":"Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE trial","volume":"205","author":"Nathan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.amjms.2023.03.002_bib0023","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.amjms.2023.03.002_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001310","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"9","key":"10.1016\/j.amjms.2023.03.002_bib0025","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1007\/s12325-022-02229-8","article-title":"The antifibrotic effects of inhaled treprostinil: an emerging option for ILD","volume":"39","author":"Kolb","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.amjms.2023.03.002_bib0026","doi-asserted-by":"crossref","first-page":"e12063","DOI":"10.1002\/pul2.12063","article-title":"BREEZE: Open-label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI\u2122 in patients with pulmonary arterial hypertension","volume":"12","author":"Spikes","year":"2022","journal-title":"Pulm Circ"},{"issue":"9","key":"10.1016\/j.amjms.2023.03.002_bib0027","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4155\/tde-2019-0062","article-title":"Dry powder inhalers: upcoming platform technologies for formulation development","volume":"10","author":"Mehta","year":"2019","journal-title":"Ther Deliv"},{"key":"10.1016\/j.amjms.2023.03.002_bib0028","unstructured":"Koninklijke Philips N.V. I-neb AAD System - Battery Powered Drug Delivery System, https:\/\/www.usa.philips.com\/healthcare\/product\/HC85167\/i-neb-battery-powered-drug-delivery-system."},{"issue":"Suppl 1","key":"10.1016\/j.amjms.2023.03.002_bib0029","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.1089\/jamp.2010.0818","article-title":"Intelligent nebulizers in the age of the internet: the I-neb adaptive aerosol delivery (AAD) system","volume":"23","author":"Dhand","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.amjms.2023.03.002_bib0030","unstructured":"Corporation UT. Tyvaso Inahaltion System TD-300: Instrucions for Use. 2021."},{"key":"10.1016\/j.amjms.2023.03.002_bib0031","unstructured":"Corporation UT. Tyvaso Inhalation System TD-100: Instructions for Use. 2014."},{"key":"10.1016\/j.amjms.2023.03.002_bib0032","unstructured":"Corporation UT. Tyvaso Inhalation Powder DPI: Instructions for Use. 2022."},{"issue":"12","key":"10.1016\/j.amjms.2023.03.002_bib0033","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study","volume":"183","author":"Jing","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.amjms.2023.03.002_bib0034","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1291\/hypres.29.123","article-title":"Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension","volume":"29","author":"Aizawa","year":"2006","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1016\/j.amjms.2023.03.002_bib0035","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/icvts\/ivx108","article-title":"Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan","volume":"25","author":"Ried","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"10.1016\/j.amjms.2023.03.002_bib0036","doi-asserted-by":"crossref","first-page":"A2162","DOI":"10.1016\/j.chest.2020.08.1860","article-title":"Acute hemodynamic improvement in chronic pulmonary arterial hypertension on dual therapy following RT234 inhalation","volume":"158","author":"ND","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.amjms.2023.03.002_bib0037","series-title":"A Phase 1 Single and Multiple Ascending Dose (SAD\/MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AV-101, a Novel Inhaled Dry Powder Formulation of Imatinib in Healthy Subjects","first-page":"A3594","author":"Gillies RN","year":"2022"},{"issue":"10","key":"10.1016\/j.amjms.2023.03.002_bib0038","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.amjms.2023.03.002_bib0039","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjms.2023.03.002_bib0040","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12931-022-02189-1","article-title":"Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC","volume":"23","author":"Becker-Pelster","year":"2022","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.amjms.2023.03.002_bib0041","doi-asserted-by":"crossref","first-page":"9605","DOI":"10.1038\/s41598-020-66433-8","article-title":"Inhaled nitric oxide therapy in acute bronchiolitis: a multicenter randomized clinical trial","volume":"10","author":"Goldbart","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.amjms.2023.03.002_bib0042","article-title":"Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults","author":"Gebistorf","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.amjms.2023.03.002_bib0043","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/s13054-022-04158-y","article-title":"Evaluation of inhaled nitric oxide (iNO) treatment for moderate-to-severe ARDS in critically ill patients with COVID-19: a multicenter cohort study","volume":"26","author":"Al Sulaiman","year":"2022","journal-title":"Crit Care"},{"issue":"2","key":"10.1016\/j.amjms.2023.03.002_bib0044","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chest.2020.02.016","article-title":"A randomized, double-blind, placebo-controlled study of pulsed, inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis","volume":"158","author":"Nathan","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.amjms.2023.03.002_bib0045","series-title":"Proceedings of the ISHTL 42nd annual meeting & scientific sessions","article-title":"Risk assessment in pulmonary arterial hypertension (PAH): insights from the INSPIRE study with LIQ861","author":"Sahay","year":"2022"},{"issue":"2","key":"10.1016\/j.amjms.2023.03.002_bib0046","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020548","article-title":"Development and characterization of treprostinil palmitil inhalation aerosol for the investigational treatment of pulmonary arterial hypertension","volume":"22","author":"Plaunt","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjms.2023.03.002_bib0047","series-title":"Proceedings of the ERS international congress","article-title":"Inhaled liposomal treprostinil (L606) shows extended release in healthy volunteer, as well as prolongs pharmacological effect in hypoxia-induced rat","volume":"56","author":"K-JC","year":"2020"},{"issue":"7","key":"10.1016\/j.amjms.2023.03.002_bib0048","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.023021","article-title":"Platelet-derived growth factor receptor type alpha activation drives pulmonary vascular remodeling via progenitor cell proliferation and induces pulmonary hypertension","volume":"11","author":"Solinc","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"10.1016\/j.amjms.2023.03.002_bib0049","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"issue":"11","key":"10.1016\/j.amjms.2023.03.002_bib0050","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.healun.2015.05.025","article-title":"Long-term safety and efficacy of imatinib in pulmonary arterial hypertension","volume":"34","author":"Frost","year":"2015","journal-title":"J Heart Lung Transpl"},{"key":"10.1016\/j.amjms.2023.03.002_bib0051","doi-asserted-by":"crossref","first-page":"A2325","DOI":"10.1016\/j.chest.2022.08.1923","article-title":"Inhaled imatinib for pulmonary arterial hypertension clinical trial: design of the impact phase 2b\/3 study design","volume":"162","author":"MMC","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.amjms.2023.03.002_bib0052","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02356-2021","article-title":"Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension","author":"Galkin","year":"2022","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.amjms.2023.03.002_bib0053","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211057071","article-title":"TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension","volume":"11","author":"Frantz","year":"2021","journal-title":"Pulm Circ"},{"issue":"10","key":"10.1016\/j.amjms.2023.03.002_bib0054","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S2213-2600(22)00097-2","article-title":"Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis","volume":"10","author":"Hoeper","year":"2022","journal-title":"Lancet Respir Med"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962923010613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962923010613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:42:40Z","timestamp":1757702560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962923010613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0002962923010613"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2023.03.002","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary hypertension inhaled therapies: An updated review","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}